Mgr. Zuzana Jašková, Ph.D.

Researcher, Biobank and CELSPAC Laboratories

Correspondence Address:
Kotlářská 267/2, 611 37 Brno

Office: bldg. D29/1S118
Kamenice 753/5
625 00 Brno

Phone:	+420 549 49 4793
E‑mail:

Inactive employment status

Basic information

Supervision

Qualifications

Publications

Type

Total number of publications: 18

2014

Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab

ŠEBEJOVÁ Ludmila BORSKÝ Marek JAŠKOVÁ Zuzana POTĚŠIL David NAVRKALOVÁ Veronika MALČÍKOVÁ Jitka ŠRÁMEK Martin DOUBEK Michael LOJA Tomáš POSPÍŠILOVÁ Šárka MAYER Jiří TRBUŠEK Martin

Article in Periodical

Experimental Hematology, year: 2014, volume: 42, edition: 10, DOI
Reactivation of mutated p53 in chronic lymphocytic leukemia cells using prima-1 met.

JAŠKOVÁ Zuzana ŠEBEJOVÁ Ludmila BRYCHTOVÁ Yvona DOUBEK Michael POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Conference abstract

Year: 2014, type: Conference abstract

2013

Mutace v genu TP53 jsou spojeny s vyšší rezistencí CLL buněk na ofatumumab a rituximab in vitro

ŠEBEJOVÁ Ludmila ŠRÁMEK Martin JAŠKOVÁ Zuzana BORSKÝ Marek POTĚŠIL David NAVRKALOVÁ Veronika MALČÍKOVÁ Jitka BRYCHTOVÁ Yvona DOUBEK Michael MAYER Jiří POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Conference abstract

Year: 2013, type: Conference abstract
Reactivation of selected p53 mutants in B-cell tumor cell lines using targeted small molecules

JAŠKOVÁ Zuzana ŠEBEJOVÁ Ludmila POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Conference abstract

Year: 2013, type: Conference abstract
Reaktivace vybraných p53 mutantů u B-buněčných nádorových linií prostřednictvím malých cílených molekul

JAŠKOVÁ Zuzana ŠEBEJOVÁ Ludmila POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Conference abstract

Year: 2013, type: Conference abstract
The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells

NAVRKALOVÁ Veronika ŠEBEJOVÁ Ludmila ZEMANOVÁ Jana JAŠKOVÁ Zuzana TRBUŠEK Martin

Article in Periodical

Leukemia & Lymphoma, year: 2013, volume: 54, edition: 8, DOI
TP53 mutations associate with higher in vitro resistance of CLL cells to ofatumumab and rituximab

ŠEBEJOVÁ Ludmila ŠRÁMEK Martin JAŠKOVÁ Zuzana BORSKÝ Marek POTĚŠIL David NAVRKALOVÁ Veronika MALČÍKOVÁ Jitka BRYCHTOVÁ Yvona DOUBEK Michael MAYER Jiří POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Conference abstract

Year: 2013, type: Conference abstract
TP53 mutations but not ATM mutations associate with higher in vitro resistance of CLL cells to rituximab

ŠEBEJOVÁ Ludmila ŠRÁMEK Martin JAŠKOVÁ Zuzana MALČÍKOVÁ Jitka NAVRKALOVÁ Veronika BORSKÝ Marek DOUBEK Michael MAYER Jiří POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Conference abstract

Year: 2013, type: Conference abstract

Projects

Teaching

10 reasons why you will fall in love with MU

Ask our ambassador

Read about research at MU

Mgr. Zuzana Jašková, Ph.D.

2014

Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab

Reactivation of mutated p53 in chronic lymphocytic leukemia cells using prima-1 met.

2013

Mutace v genu TP53 jsou spojeny s vyšší rezistencí CLL buněk na ofatumumab a rituximab in vitro

Reactivation of selected p53 mutants in B-cell tumor cell lines using targeted small molecules

Reaktivace vybraných p53 mutantů u B-buněčných nádorových linií prostřednictvím malých cílených molekul

The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells

TP53 mutations associate with higher in vitro resistance of CLL cells to ofatumumab and rituximab

TP53 mutations but not ATM mutations associate with higher in vitro resistance of CLL cells to rituximab